Brief: First AML Patient Successfully Transplanted With Vor Bio’S Investigational Trem-Cel (VOR33) And Tolerated Mylotarg
07/12/2022 12:49
Dec 7 (Reuters) - Vor Biopharma Inc VOR.O :
* FIRST AML PATIENT SUCCESSFULLY TRANSPLANTED WITH VOR BIO’S
INVESTIGATIONAL TREM-CEL (VOR33) AND TOLERATED MYLOTARG™
* VOR BIOPHARMA INC- CLINICAL TRIAL CONTINUES TO ENROLL
PATIENTS
AND ADDITIONAL DATA ARE EXPECTED IN 2023
Source text for Eikon: ID:nGNX2tP23x
Further company coverage: VOR.O
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning